Abstract:Background: Metformin is a first-line drug for treating type 2 diabetes and has gained considerable interest as a potential anticancer agent. Increasing evidence suggests that metformin antagonizes diabetes and tumors through disrupting metabolic homeostasis and altering energy state. However, whether AMP activated protein kinase (AMPK) contributes to such effects of metformin remains controversial. Methods: We performed integrative metabolomics analyses to systematically examine the effects of metformin on metabolic pathways in Prkaa1 wild type (WT) and knock-out (KO) mouse embryonic fibroblast (MEF) cells as well as human cells based on gas chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry (CE-MS). Results: Metformin treatment induced metabolic reprogramming and reduced the energy state of both Prkaa1 WT and KO MEF cells, as evidenced by suppressed tricarboxylic acid (TCA) cycle, elevated lactate production as well as decreased NAD+/NADH ratio. Additionally, metabolic flux analysis also showed that metformin Ampkα-independently increased metabolic flux from glucose to lactate and decreased metabolic flux from acetyl-CoA to TCA cycle as well as from pyruvate to malate. Moreover, metformin Ampkα-dependently upregulated P-Acc but Ampkα-independently inhibited the levels of P-mTor, P-S6, Lc3, Atgl and P-Erk in MEF cells. Similarly, we demonstrated that a commonly used AMPK agonist 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) and fetal bovine serum (FBS) starvation, as a common model for energy stress, both led to Ampkα-independent metabolism alterations in MEF cells. Furthermore, these effects of metformin were also confirmed in human hepatocellular carcinoma (HCC) cells as well as in MCF10A shControl and shPRKAA1 cells. Importantly, we found that metformin could obviously inhibit colony conformation of HCC cells in an Ampkα-independent manner. Conclusions: Our data highlight a comprehensive view of metabolic reprogramming mediated by metformin as well as AICAR. These observations suggest that metformin could affect cellular metabolism largely bypassing Ampkα, and may provide a new insight for its clinical usage.

Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53

Metformin Protects Endothelial Function in Diet-Induced Obese Mice by Inhibition of Endoplasmic Reticulum Stress Through 5′ Adenosine Monophosphate–Activated Protein Kinase–Peroxisome Proliferator–Activated Receptor Δ Pathway

AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice

Metformin Attenuates Palmitic Acid-Induced Insulin Resistance In L6 Cells Through The Amp-Activated Protein Kinase/Sterol Regulatory Element-Binding Protein-1c Pathway

Metformin inhibits the growth of pancreatic cancer cells by inducing degradation of mutant p53 protein

Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21

Activation of AMPK/mTORC1-Mediated Autophagy by Metformin Reverses Clk1 Deficiency-Sensitized Dopaminergic Neuronal Death

p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells

Metformin promotes autophagy in ischemia/reperfusion myocardium via cytoplasmic AMPKα1 and nuclear AMPKα2 pathways

Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Involvement of Catalase in the Protective Benefits of Metformin in Mice with Oxidative Liver Injury.

A Role for PFKFB3/iPFK2 in Metformin Suppression of Adipocyte Inflammatory Responses

Metformin-induced AMPK activation promotes cisplatin resistance through PINK1/Parkin dependent mitophagy in gastric cancer

Metformin Alleviates HFD-induced Oxidative Stress in Hepatocyte Via Activating SIRT6/PGC-1α/ENDOG Signaling

Metformin ameliorates insulin resistance in L6 rat skeletal muscle cells through upregulation of SIRT3

Parkin, A P53 Target Gene, Mediates the Role of P53 in Glucose Metabolism and the Warburg Effect

Low-dose metformin targets the lysosomal AMPK pathway through PEN2

Role of p53 Family Proteins in Metformin Anti-Cancer Activities

Metformin Collaborates with PINK1/Mfn2 Overexpression to Prevent Cardiac Injury by Improving Mitochondrial Function

Metformin Plays a Dual Role in MIN6 Pancreatic β Cell Function through AMPK-dependent Autophagy